ESMO 2023: Focus on Lung Cancer
Innovative data and breaking news from the European Society for Medical Oncology Congress, taking place in Madrid, Spain, October 20-24, 2023.
Results of a study explored the potential of automated lung tumor vascularity.
A study assessed unmet needs as well as QOL and FT in survivors of NSCLC.
A study assessed differences in lung cancer screening eligibility among lung cancer survivors.
Depression is common in patients with lung cancer and those with type 2 diabetes.
Potential of Volatile Organic Compounds as a Noninvasive Method for Early Detection of EGFR Mutation
VOCs are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma.
A study examined the impact of the Interception-Lung program, which aims to reduce the incidence of advanced lung cancer.
A study evaluated the prognosis of patients with locally advanced and metastatic NSCLC who underwent prior TKI.
The study aimed to investigate the relationship between tobacco use and lung cancer.
The TROPION-Lung07 trial will evaluate Dato-DXd plus pembrolizumab in patients with advanced/metastatic NSCLC.
A study analyzed the clinicopathological characteristics of small-scale ROS1 mutations in patients with NSCLC.
A study looked at the modulating effects of neoadjuvant immunotherapy and CRT on TDLN in patients with T2-4NO-1 NSCLC.
A study compared IMPT with IMRT its impact on hematological toxicity and effect on durvalumab treatment on NSCLC.
A study investigated the overlap between patients with COPD and patients examined on suspicion of lung cancer.
Results of a study examining the association between HRD status and postsurgical therapeutic options in early-stage NSCLC.
Results of a study that sought to determine a dynamic pattern of ctDNA during hypofractionated radiation therapy.
A study investigated the use of a structured multidisciplinary review for the diagnosis of IO pneumonitis in NSCLC.
A study used a preoperative machine learning model to predict lung cancer recurrence.
Targeted therapies and platinum-based chemotherapy may become ineffective in patients with a/mNSCLC with AGAs.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.